219 related articles for article (PubMed ID: 29783729)
1. Chlorogenic Acid Improves the Regorafenib Effects in Human Hepatocellular Carcinoma Cells.
Refolo MG; Lippolis C; Carella N; Cavallini A; Messa C; D'Alessandro R
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783729
[TBL] [Abstract][Full Text] [Related]
2. The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma.
Yu CC; Huang SY; Chang SF; Liao KF; Chiu SC
Molecules; 2020 May; 25(10):. PubMed ID: 32466169
[TBL] [Abstract][Full Text] [Related]
3. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.
El-Hanboshy SM; Helmy MW; Abd-Alhaseeb MM
Mol Biol Rep; 2021 Nov; 48(11):7233-7242. PubMed ID: 34596810
[TBL] [Abstract][Full Text] [Related]
4. Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1237-1245. PubMed ID: 25907508
[TBL] [Abstract][Full Text] [Related]
5. Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1.
Lippolis C; Refolo MG; D'Alessandro R; Carella N; Messa C; Cavallini A; Carr BI
J Exp Clin Cancer Res; 2015 Sep; 34(1):90. PubMed ID: 26329608
[TBL] [Abstract][Full Text] [Related]
6. Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells.
Wu LW; Zhou DM; Zhang ZY; Zhang JK; Zhu HJ; Lin NM; Zhang C
Biochem Biophys Res Commun; 2019 May; 512(4):852-858. PubMed ID: 30929918
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways.
Subramonian D; Phanhthilath N; Rinehardt H; Flynn S; Huo Y; Zhang J; Messer K; Mo Q; Huang S; Lesperance J; Zage PE
Br J Cancer; 2020 Aug; 123(4):568-579. PubMed ID: 32457362
[TBL] [Abstract][Full Text] [Related]
8. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
[TBL] [Abstract][Full Text] [Related]
9. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
10. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
11. CXC195 induces apoptosis and endoplastic reticulum stress in human hepatocellular carcinoma cells by inhibiting the PI3K/Akt/mTOR signaling pathway.
Chen XL; Fu JP; Shi J; Wan P; Cao H; Tang ZM
Mol Med Rep; 2015 Dec; 12(6):8229-36. PubMed ID: 26496900
[TBL] [Abstract][Full Text] [Related]
12. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib delays the proliferation of hepatocellular carcinoma by inducing autophagy.
Han R; Li S
Pharmazie; 2018 Apr; 73(4):218-222. PubMed ID: 29609689
[TBL] [Abstract][Full Text] [Related]
14. Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases.
Yan Y; Li J; Han J; Hou N; Song Y; Dong L
Anticancer Drugs; 2015 Jun; 26(5):540-6. PubMed ID: 25714249
[TBL] [Abstract][Full Text] [Related]
15. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
17. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
18. Chlorogenic acid inhibits hepatocellular carcinoma in vitro and in vivo.
Yan Y; Liu N; Hou N; Dong L; Li J
J Nutr Biochem; 2017 Aug; 46():68-73. PubMed ID: 28458139
[TBL] [Abstract][Full Text] [Related]
19. Chlorogenic Acid Targeting of the AKT PH Domain Activates AKT/GSK3β/FOXO1 Signaling and Improves Glucose Metabolism.
Gao J; He X; Ma Y; Zhao X; Hou X; Hao E; Deng J; Bai G
Nutrients; 2018 Sep; 10(10):. PubMed ID: 30249058
[TBL] [Abstract][Full Text] [Related]
20. Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells.
Pan ST; Qin Y; Zhou ZW; He ZX; Zhang X; Yang T; Yang YX; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1601-26. PubMed ID: 25834400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
